Table 1.
Study population characteristics
| All women (n=461) | Sexually-active women (n=386) | |
|---|---|---|
| Mean age at diagnosis (SD) | 35.6 (4.0) | 35.5 (4.0) |
| Range | 17–40 | 22–40 |
| Mean time from diagnosis months (SD) | 12.7 (1.7) | 12.7 (1.7) |
| Range | 7.8–21.6 | 7.9–21.6 |
| Mean CARES sexual interest score (SD) | 1.11 (1.03) | 0.99 (0.97) |
| Range | 0–4 | 0–4 |
| Mean CARES sexual dysfunction score (SD) | ---- | 1.52 (1.22) |
| Range | --- | 0–4 |
| N (%) | N (%) | |
| Partner status | ||
| Partnered | 396 (86) | 359 (93) |
| Non-partnered | 65 (14) | 27 (7) |
| Race | ||
| WNH | 413 (90) | 349 (90) |
| Non-WNH | 48 (10) | 37 (10) |
| Incomea | ||
| <$25,000 | 23 (5) | 18 (5) |
| $25,000–$49,999 | 36 (8) | 25 (6) |
| $50,000–$99,999 | 135(29) | 111 (29) |
| ≥$100,000 | 225 (49) | 198 (51) |
| Don’t know | 4 (1) | 3 (1) |
| College educationb | ||
| Yes | 376 (85) | 315 (85) |
| No | 67 (15) | 56 (15) |
| Stage | ||
| 0 | 35 (8) | 32 (8) |
| I | 173 (38) | 150 (39) |
| II | 197 (43) | 157 (41) |
| III | 56 (12) | 47 (12) |
| Estrogen receptor statusc | ||
| Positive | 322 (70) | 276 (72) |
| Negative | 137 (30) | 108 (28) |
| Chemotherapy | ||
| Yes | 351 (76) | 288 (75) |
| No | 110 (24) | 98 (25) |
| Tamoxifen | ||
| Yes | 272 (59) | 231 (60) |
| No | 189 (41) | 155 (40) |
| Ovarian suppression | ||
| Yes | 104 (23) | 82 (21) |
| No | 357 (77) | 304 (79) |
| Treatment-associated amenorrhea | ||
| Amenorrhea (due to chemotherapy or ovarian suppression) | 210 (46) | 172 (45) |
| No amenorrhea/Chemotherapy | 164 (36) | 138 (36) |
| No amenorrhea/ No chemotherapy | 87 (19) | 76 (20) |
| Radiation | ||
| Yes | 266 (58) | 213 (55) |
| No | 195 (42) | 173 (45) |
| Surgery | ||
| Lumpectomy | 142 (31) | 113 (29) |
| Mastectomy | 60 (13) | 48 (12) |
| Mastectomy with reconstruction | 259 (56) | 225 (58) |
Abbreviations: CARES, Cancer Rehabilitation Evaluation System; SD, Standard Deviation; WNH, White non-Hispanic
a
n=38/461 missing;
b
n=18/461 missing;
c
n=2/461 missing